鲨鱼
China approves first-ever drug for acute mountain sickness prevention_我的网站
A |
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness.
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source.
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations.
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。
B | 讯 据公安部网安局消息，公安机关网安部门依托“净网—2026”专项行动，持续严厉打击编造传播涉台风等网络谣言违法犯罪活动。
C | 今日，公安部网安局再次公布4起典型案例： 案例1 网民王某某（男，35岁）因台风天气，暂住在临时安置点，为博取关注、吸粉引流，编造传播“安置点停水停电”“群众无饭吃”“设立难民营”等系列网络谣言，引发大量网民误读，并在抖音平台直播时编造“杭州台风致人打地铺吃不上饭”的虚假内容，伺机向网友索要打赏，牟取非法利益。
D | 目前，该王已被属地公安机关依法行政处罚。 案例2 网民孙某某（男，50岁）在当地未出现台风积水险情的情况下，为博取流量，将往年水灾视频重新发布到抖音平台，引发传播扩散，误导当地居民，制造公众焦虑，影响防汛救灾工作正常开展。 目前，该孙已被属地公安机关依法行政处罚。 案例3 网民王某某（男，46岁）为博取关注、吸粉引流，使用AI工具生成主要内容为“此刻＊＊公园景象，台风影响，湖水即将溢出”的网络谣言，并在微信平台发布，误导大量网民关注和讨论，扰乱公共秩序，影响防汛救灾工作正常开展。 目前，该王已被属地公安机关依法行政处罚。
E | 案例4 网民叶某某（男，50岁）为博取关注、吸粉引流，将往年水灾视频进行剪辑、拼接，谎称“＊＊出现台风积水险情”，误导大量网民关注和讨论，造成部分当地民众恐慌，影响防汛救灾工作正常开展。 目前，该叶已被属地公安机关依法行政处罚。版权申明：凡注有“”或电头为“”的稿件，均为独家版权所有，未经许可不得转载或镜像；授权转载必须注明来源为“”，并保留“”的电头。 。
Current article:http://uyea1.shaihanhuangwoshang.cyou/list_jnjifv/ugznj3.html
Published on:01:03:46